A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy

R. Wagner, Kathryn; L. Fleckenstein, James; A. Amato, Anthony; J. Barohn, Richard; Bushby, K.; M. Escolar, Diana; M. Flanigan, Kevin; Pestronk, Alan; Tawil, Rabi; I. Wolfe, Gil; Eagle, Michelle; Florence, Julaine; King, Wendy; Pandya, Shree; Straub, Volker; Juneau, Paul; N. Meyers, Kathleen; Csimma, Cristina; Araujo, Tracey; H. Allen, Robert; A. Parsons, Stephanie; M. Wozney, John; R. LaVallie, Edward; R. Mendell, Jerry

doi:10.1002/ana.21338

Public

A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy

Published in Annals of Neurology • Mar 11, 2008

Authors:

Kathryn R. Wagner

James L. Fleckenstein

Anthony A. Amato

Abstract

OBJECTIVE: Myostatin is an endogenous negative regulator of muscle growth and a novel target for muscle diseases. We conducted a safety trial of a neutralizing antibody to myostatin, MYO-029, in adult muscular dystrophies (Becker muscular dystrophy, facioscapulohumeral dystrophy, and limb-girdle mus...

Subject

Medicine

Muscular dystrophy

Cohort

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!